|
Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial. |
|
|
Consulting or Advisory Role - MSD |
Research Funding - MSD (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Isabelle Scheer-Senyarich |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BMS Brazil; Janssen |
Travel, Accommodations, Expenses - Abbvie; BMS Brazil; Janssen; Merck |
|
|
Honoraria - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Roche (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - MSD (Inst) |
|
|
No Relationships to Disclose |